EDAP TMS S.A. (EDAP) Reports Q1 Loss of EUR0.10

Go back to EDAP TMS S.A. (EDAP) Reports Q1 Loss of EUR0.10

EDAP Reports First Quarter 2015 Results

May 12, 2015 4:05 PM EDT

1Q 2015 and Recent Operational Highlights

Direct De Novo petition for Ablatherm HIFU submitted to the FDA in April 2015; Treatment-driven revenue from the HIFU division increased 17% year-over-year; Revenue for first quarter 2015 totaled EUR 6.2 million (USD 6.9 million); Canadian regulatory approval of Focal One; first device sold and initial patients successfully treated Cash position remains strong at EUR 11.3 million (USD 12.1 million) as of March 31, 2015;

LYON, France, May 12, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced financial results for the first... More